Plain-English translation of NCT07225270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called Rinatabart Sesutecan (), given as a maintenance treatment after chemotherapy, can help prevent ovarian cancer from coming back. The study will compare people who receive this medication along with standard care against people who receive standard care alone. The standard care may include (a different medication) or observation without additional treatment.
Ovarian cancer often returns even after chemotherapy works well the first time. Doctors are looking for better ways to keep the cancer from coming back longer, and this medication is being tested to see if it can help prevent recurrence.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication plus standard care, or standard care alone. You will visit the clinic regularly so doctors can monitor how you're doing, check for side effects, and scan or test to see if your cancer stays under control. The study involves 544 people total, and you would be followed over time to see how long it takes for cancer to return, if at all.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
United States